Biomarkers of Social Sensitivity in Major Depression (SENSO)

Etude de la sensibilité Aux Signaux Sociaux Dans la dépression, Modulateurs Psychologiques, Comportementaux et Inflammatoires.

Major depression disorder (MDD) is a frequent and disabling mental disorder with great risk of recurrence and chronicity. Interpersonal factors are among the strongest predictors of the course and duration of an episode of depression. More specifically, social rejection is one of the most environmental risk factors of MDD. Targeted rejection predicts hastened onset of major depression. On the other hand, healthy subject show prosocial behavior after social rejection to reconnect to new source of social interaction. In addition to the potential impact of social exclusion on MDD onset, depressed patients may be more prone to be rejected as they encounter interpersonal difficulties and may less be able to reconnect to the social group after rejection.

Recent neuroimaging data show that brain processing of social exclusion activate brain regions that are central to the pathophysiology of MDD. Some of these regions are also known to be activated during physical pain and may contribute to the aversive dimension of the experienced rejection. Pro-inflammatory cytokines are involved in MDD physiopathology and can induce social withdrawal behavior. Inflammation can modulate social interactions in mammals. Moreover, after a social stress such as social rejection, blood cytokines increase. At a cognitive level, self-esteem can modulate the sensitivity to social rejection.

The major objective of the trial is to study sensitivity to social signals in MDD patient compared to healthy subject.

The investigators hypothesize in MDD patient : (1) decrease of rapid facial reactions (RFR) to dynamic emotional faces expressing joy, (2) increase of RFR to dynamic emotional faces expressing sadness, (3) decrease of prosocial reaction after experimental social rejection.

Secondary objective is to identify psychological and biological mediators We hypothetize in MDD patient: (1)mediating effect of systemic inflammatory cytokines, an (2) mediating effect of state self esteem 30 MDD patients and 60 healthy subject will be included. They will encounter psychiatric and psychometric evaluation. Their facial EMG will be recorded to assess RFR to dynamic emotional faces created by photo morphing from KDEF emotional faces database, coupled to occulometric recording. Subjects will perform cyberball game as an experimental inclusion or exclusion task and the trustgame task as an implicit evaluation of their prosocial behavior. Questionnaires will assess explicit measurement of social rejection pain and desire of affiliation. Inflammatory markers will be measured in a blood sample before the cyberball task for every subjects and 6 hours later for 20 healthy volunteers. Dosage of IL-6, IL-10, TNFa, IP-10, MCP-1, MIP-1b, Rantes, sIL-6Ra, IL1ra, VEGF, Leptin, PECAM1, sTie2, sVEGFR1, sVEGFR2 will be performed by luminex technique and usCRP, srIL2 ans sCD14 by ELISA technique.

Study Overview

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75013
        • ICM, Pitié Salpêtrière Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

  1. st group : major depression disorder patients
  2. nd group : healthy volunteers

Description

Inclusion Criteria:

For everybody :

  • benefit social health insurance
  • french speaker and reader
  • can stop smoking one day
  • volunteer to participate

For 1st group :

  • actual MDD diagnosed by a psychiatrist and meet the DSM IV criterias of MDD
  • no antidepressant treatment or antidepressant treatment for less than 7 days.

Exclusion Criteria:

  • BMI > 40
  • weekly sport > 3 hours
  • pregnancy
  • fever or other infection symptoms during the last month
  • significant or unstable disease, especially neurologic or inflammatory.
  • recent history of coronary disease, ulcer, COPD, severe dyslipemia, kidney or liver failure.
  • severe smoking addiction (fagerström > 8)
  • antiinflammatory or immunomodulatory treatment during last month

For 1st group :

  • no psychiatric treatment except benzodiazepin if no severe vigilance trouble and antidepressant treatment more than 7 days
  • subjects under legal protection
  • constraint hospitalization
  • significant suicidal risk
  • resistant MDD
  • psychiatric comorbidity

For 2nd group :

- psychiatric disease, actual or past according to DSM IV criterias

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MDD patients
emotional facial stimuli cyberball game
Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
healthy subjects
emotional facial stimuli cyberball game
Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rapid facial reactions : milliVolts amplitude of electromyographic signal of zygomaticus, corrugator, depressor & frontalis muscles
Time Frame: During stimuli presentation (emotional faces) at Day 1 from 9:40 to 10:30 am
During passive watching of dynamic emotional faces, electromyographic signal is recorded with skin electrodes facing zygomaticus, corrugator, depressor & frontalis muscles.
During stimuli presentation (emotional faces) at Day 1 from 9:40 to 10:30 am
Implicit pro-social behavior : invested money during a 4-round trust game
Time Frame: At Day 1 from 11:40 to 11:50 am
Total amount of money invested by the subject during a 4-round trust game without feedback.
At Day 1 from 11:40 to 11:50 am
Explicit pro-social behavior : affiliation desire measured by a questionnaire
Time Frame: At Day 1 from 11:50 to 12:00 am
Affiliation desire questionnaire from Park and Manner assessing total affiliation desire and affiliation desire towards close relationship or strangers.
At Day 1 from 11:50 to 12:00 am

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self esteem assessed by questionnaires mediates social pain after rejection and pro-social behavior
Time Frame: 2 assessments at Day 1 : at 8:30 and at 11:50 am
Scoring of questionnaires of state and trait self esteem (state self esteem scale and Rosenberg scale)
2 assessments at Day 1 : at 8:30 and at 11:50 am
Systemic inflammation mediates social pain after rejection and pro-social behavior
Time Frame: At day 1 : at 11:30 am and 5:30 pm

Inflammatory dosage in blood :

  • IL-6, IL-10, TNFa, IP-10, MCP-1, MIP-1b, Rantes, sIL-6Ra, IL1ra, VEGF, Leptin, PECAM1, sTie2, sVEGFR1, sVEGFR2 by luminex technique
  • usCRP, srIL2 ans sCD14 by ELISA technique.
At day 1 : at 11:30 am and 5:30 pm

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2014

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

June 30, 2014

First Submitted That Met QC Criteria

August 8, 2014

First Posted (Estimate)

August 12, 2014

Study Record Updates

Last Update Posted (Actual)

August 30, 2021

Last Update Submitted That Met QC Criteria

August 27, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on emotional facial stimuli

Subscribe